Posted in M&A / Deals Roche sticks with C4T, adding up to $1B for molecular glue partnership April 9, 2026 BioSpace Roche is jumping into degrader-antibody conjugates, a modality that in recent years has attracted investments from Merck KGaA and Bristol Myers Squibb. M&A / DealsRead full story